美诺华：控股子公司阿托伐他汀钙原料药上市申请获批

Core Viewpoint - The announcement indicates that Meinuohua's subsidiary has received approval for the production of atorvastatin calcium, a drug used for treating high cholesterol and preventing coronary heart disease [1] Group 1: Company Developments - Meinuohua's subsidiary, Xuancheng Meinuohua Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration for atorvastatin calcium raw material [1] - Atorvastatin calcium is indicated for the treatment of hypercholesterolemia and mixed dyslipidemia, as well as for the prevention and treatment of coronary heart disease [1]